ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2019
Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Efficacy of WRSs2, a live-attenuated Shigella sonnei vaccine, against shigellosis in a controlled human infection model in the USA: a phase 2, double-blind, randomised, placebo-controlled trial.The Lancet. Infectious diseases · 2026Article
- Shigella sonnei: epidemiology, evolution, pathogenesis, resistance and host interactions.Nature reviews. Microbiology · 2025Review
- Antibiotic resistance and molecular characterization of clinical Shigella spp. isolated from hospitals located in Tehran and Qazvin cities, Iran.BMC research notes · 2025Article
- Detonating a "time bomb": how enteric infection stress triggers prophage induction in commensal microbiota and exacerbates disease progression.Frontiers in microbiology · 2025Review
- Organ-on-chip models for infectious disease research.Nature microbiology · 2024Review
- Fourth Controlled Human Infection Model (CHIM) meeting - CHIMs in endemic countries, May 22-23, 2023.Biologicals : journal of the International Association of Biological Standardization · 2024Article
- Efficacy Evaluation of an Intradermally Delivered EnterotoxigenicMicroorganisms · 2024Article
- The Background, Role and Approach for Development of a Controlled Human Infection Model for Nontyphoidal Salmonella.Current topics in microbiology and immunology · 2024Review
- The Controlled Human Infection Model for Enterotoxigenic Escherichia coli.Current topics in microbiology and immunology · 2024Review
- Shigella-Controlled Human Infection Models: Current and Future Perspectives.Current topics in microbiology and immunology · 2024Review
- Article
- Article
- Controlled Human Infection Models To Accelerate Vaccine Development.Clinical microbiology reviews · 2022Review
- TheVaccines · 2022Review
- Controlled human infectious models, a path forward in uncovering immunological correlates of protection: Lessons from enteric fevers studies.Frontiers in microbiology · 2022Review
- Article
- Establishment of a Controlled Human Infection Model with a Lyophilized Strain of Shigella sonnei 53G.mSphere · 2020Article
- Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G.mSphere · 2020Article
- Controlled Human Infection to Speed Up SARS-CoV-2 Vaccine Development.Frontiers in immunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 1 country.
Funding
Abstract
Shigella causes morbidity and mortality worldwide, primarily affecting young children living in low-resource settings. It is also of great concern due to increasing antibiotic resistance, and is a priority organism for the World Health Organization. A Shigella vaccine would decrease the morbidity and mortality associated with shigellosis, improve child health, and decrease the need for antibiotics. Controlled human infection models (CHIMs) are useful tools in vaccine evaluation for early up- or down-selection of vaccine candidates and potentially useful in support of licensure. Over time, the methods employed in these models have become more uniform across sites performing CHIM trials, although some differences in conduct persist. In November 2017, a Shigella CHIM workshop was convened in Washington, District of Columbia. Investigators met to discuss multiple aspects of these studies, including study procedures, clinical and immunological endpoints, and shared experiences. This article serves as a uniform procedure by which to conduct Shigella CHIM studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.